Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | PRF1 | P14222 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096709 | 0.86 | PIK3CA (0.51) | PIK3CAPIK3CGPIK3CBMTORCDK19 | |
| SCHEMBL3095115 | 0.85 | PIK3CG (0.60) | PIK3CAPIK3CGPIK3CBMTORCDK19 | |
| SCHEMBL3077971 | 0.83 | PIK3CA (0.48) | PIK3CAPIK3CGPIK3CBMTORCDK19 | |
| SCHEMBL3083732 | 0.81 | MAPK1 (0.40) | PIK3CAPIK3CBMTORNTRK1 | |
| SCHEMBL3083738 | 0.81 | MAPK1 (0.40) | PIK3CAPIK3CBMTORNTRK1 | |
| SCHEMBL3084895 | 0.80 | PDGFRB (0.53) | PIK3CAPIK3CGPIK3CBMTORNTRK1 | |
| SCHEMBL3083385 | 0.79 | MAPK1 (0.46) | PIK3CAPIK3CGPIK3CBMTORCDK19 | |
| SCHEMBL3079157 | 0.79 | PIK3CG (0.47) | PIK3CAPIK3CGPIK3CBMTORCDK19 | |
| SCHEMBL13146292 | 0.79 | PIK3CG (0.51) | PIK3CAPIK3CGPIK3CBMTORCDK19 | |
| SCHEMBL3084319 | 0.79 | PIK3CB (0.50) | PIK3CAPIK3CGPIK3CBPIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008141065-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | PIK3CA 8/4885PIK3CG 3/4885PIK3CB 2/4885 |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | PIK3CA 8/4885PIK3CG 3/4885PIK3CB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.